About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
A
TGF Beta Pathway Inhibition in MDS: Luspatercept Significantly Decreases Transfusion Dependence in RARS MDS and Stimulates Late Stage of Erythroid Differentiation
By
University of Miami's 2nd Biennial Miami Leukemia Symposium
FEATURING
Amit K. Verma
By
University of Miami's 2nd Biennial Miami Leukemia Symposium
FEATURING
Amit K. Verma
104 views
May 14, 2020
0 Comments
Login to view comments.
Click here to Login
Related Content
AUTOPLAY
ON
06:46
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML U…
Feat.
S. Urrutia
10:38
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …
Feat.
D. Tremblay
11:20
Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)
SOHO 2021 Update on CMML Overview of the Most Recent Data
Feat.
G. Montalban-Bravo
10:43
Naval Daver
MD Anderson Immune Checkpoint Based Approaches in AML & MDS: Whi…
15:33
Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)
2020 SOHO Updates on Oral HMAs in MDS: Can FDA-Approved Decitabine/C…
Feat.
G. Garcia-Manero
12:19
University of Miami's 2nd Biennial Miami Leukemia Symposium
How to Calculate Risk in MDS Patients?
Feat.
M. Sekeres
18:24
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylatin…
Feat.
A. Mishra
14:59
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
In Transplant-Eligible Patients With Higher-Risk MDS, Hypomethylatin…
Feat.
R. Komrokji
21:24
University of Miami's 2nd Biennial Miami Leukemia Symposium
2020 Update on Atypical CML, CMML & CNL: Is There Clinical Benef…
Feat.
J. Tyner
11:18
Indy Hematology Review
Relapse After Allo HSCT - Treatment Strategies and Overview of Relat…
Feat.
R. Childs
14:36
University of Miami's 2nd Biennial Miami Leukemia Symposium
Frontline Therapies in MDS: Leveling Lower-risk MDS
Feat.
M. Sekeres
20:00
Moffitt Cancer Center's 16th Annual Clinical Breakthroughs & Challenges in Hematologic Malignancies
MDS/MPN Overlap Through Interactive Case Based Discussion: Overview …
Feat.
A. Kuykendall
26:41
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review on MDS: Luspatercept Under FDA Review, Novel Oral HM…
Feat.
H. Carraway
06:53
Indy Hematology Review
Chronic Myelomonocytic Leukemia: Define, Diagnosis, Prognostications…
Feat.
A. Tefferi
05:28
University of Miami's 2nd Biennial Miami Leukemia Symposium
Frontline Therapies in MDS: Hampering Higher-risk MDS
Feat.
M. Sekeres
07:01
Cleveland Clinic's 20th Annual ASH Review
2019 ASH Review of MDS: Clonal Hematopoiesis Increases Risk for Hema…
Feat.
H. Carraway
19:25
ESH iCMLf 20th Annual John Goldman Conference on Chronic Myeloid Leukaemia: Biology and Therapy
MDS/MPN: Senectus Ipsa Est Morbus (Disease of Old Age)?
Feat.
M. Deininger
20:06
University of Miami's 2nd Biennial Miami Leukemia Symposium
2020 Update on Splicing in MDS: How Can We Target Spliceosome-Mutant…
Feat.
T. Graubert
06:46
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Guadecitabine in Higher-Risk MDS and CMML U…
Feat.
S. Urrutia
10:38
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Venetoclax Improves Response Rates But Not …
Feat.
D. Tremblay
